Jul 02


CRT Investment Banking LLC n/k/a M.M. Dillon & Co. served as financial advisor and expert witness to Molecular Insight Pharmaceuticals, Inc. in connection with the Company’s chapter 11 bankruptcy in the United States Bankruptcy Court for the District of Massachusetts (Eastern Division). M.M. Dillon provided advise related to strategic and capital market alternatives, including out-licensing or divestiture of any of its products, a merger or acquisition, joint venture, spin-off, and certain financing or other strategic or capital market transactions.

About Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals, Inc. develops therapeutic radiopharmaceuticals and molecular imaging agents for use in oncology and cardiology. The company targets the development of a small-molecule chemistry platform to improve detection of primary and metastatic prostate cancer and to provide a systemic radiotherapy for relapsed and metastatic prostate cancer. Its products include technetium Tc 99m trofolastat, a clinical-stage molecular imaging agent for patients with metastatic prostate cancer; and 131I-MIP-1095, a prostate cancer therapy for systemic delivery of radiotherapy. The company was formerly known as Biostream, Inc. and changed its name to Molecular Insight Pharmaceuticals, Inc. in April 2003. The company was founded in 1997 and is based in Cambridge, Massachusetts. As of January 18, 2013, Molecular Insight Pharmaceuticals, Inc. operates as a subsidiary of Progenics Pharmaceuticals, Inc.

About M.M. Dillon & Co.

M.M. Dillon & Co. (formerly CRT Investment Banking LLC) is an employee owned partnership where industry and product specialists collaborate closely to provide creative, idea-driven advice and solutions to its institutional and corporate clients. M.M. Dillon offers public and private financing, M&A advisory and restructuring advisory services. M.M. Dillon’s team of experienced professionals provides execution capabilities for companies across a range of industry sectors. The firm’s senior banking professionals have a minimum of 20 years of experience with major Wall Street firms.